K. Sravan Emany's Insider Trades & SAST Disclosures
K. Sravan Emany's most recent trade in Beam Therapeutics Inc was a trade of 160,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Dec. 31, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern K. Sravan Emany.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Beam Therapeutics Inc | K. Sravan Emany | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 160,000 | 160,000 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | Emany Sravan K. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 80,000 | 80,000 (0%) | 0% | 0 | Common Stock | |
| Ironwood Pharmaceuticals I... | Sravan K. Emany | SVP, COO and CFO | Sale of securities on an exchange or to another person at price $ 4.08 per share. | 18 Nov 2024 | 11,001 | 309,572 (0%) | 0% | 4.1 | 44,884 | Class A Common Stock |
| Assertio Holdings Inc | Sravan K. Emany | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 81,225 | 81,225 | - | - | Stock Option (right to buy) | |
| Assertio Holdings Inc | Sravan K. Emany | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 53,750 | 231,320 (0%) | 0% | 0 | Common Stock | |
| Ironwood Pharmaceuticals I... | Sravan K. Emany | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.64 per share. | 16 May 2024 | 18,280 | 320,573 (0%) | 0% | 6.6 | 121,379 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Sravan K. Emany | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 37,120 | 338,853 (0%) | 0% | 0 | Class A Common Stock | |
| Ironwood Pharmaceuticals I... | Sravan K. Emany | SVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 37,120 | 0 | - | - | Performance-based Restricted Stock Unit | |
| Ironwood Pharmaceuticals I... | Sravan K. Emany | SVP, Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 9.38 per share. | 04 Mar 2024 | 10,684 | 301,733 (0%) | 0% | 9.4 | 100,216 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | K. Emany Sravan | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 65,312 | 291,049 (0%) | 0% | 0 | Class A Common Stock | |
| Ironwood Pharmaceuticals I... | Emany Sravan K. | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 32,656 | 32,656 | - | - | Performance-based Restricted Stock Unit | |
| Ironwood Pharmaceuticals I... | Emany K. Sravan | SVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.90 per share. | 08 Feb 2024 | 41,332 | 225,737 (0%) | 0% | 14.9 | 615,847 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Emany K. Sravan | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2024 | 85,000 | 267,069 (0%) | 0% | 0 | Class A Common Stock | |
| Ironwood Pharmaceuticals I... | Sravan K. Emany | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 74,236 | 152,658 (0%) | 0% | 0 | Class A Common Stock | |
| Ironwood Pharmaceuticals I... | Sravan K. Emany | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 37,118 | 37,118 | - | - | Performance-based Restricted Stock Units | |
| Ironwood Pharmaceuticals I... | Sravan K. Emany | SVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.56 per share. | 21 Nov 2022 | 6,578 | 78,422 (0%) | 0% | 11.6 | 76,042 | Class A Common Stock |
| Ironwood Pharmaceuticals I... | Sravan K. Emany | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2021 | 85,000 | 85,000 (0%) | 0% | 0 | Class A Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges